(Q46052972)

English

Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19362675

Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19362675

0 references

multicenter clinical trial

1 reference

based on heuristic

inferred from title

zoledronic acid

1 reference

based on heuristic

inferred from title

glucocorticoid-induced osteoporosis

1 reference

based on heuristic

inferred from title

Jean-Yves Reginster

6

object named as

Jean-Yves Reginster

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

author name string

David M Reid

1

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19362675

Jean-Pierre Devogelaer

2

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19362675

Kenneth Saag

3

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19362675

Christian Roux

4

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19362675

Chak-Sing Lau

5

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19362675

Philemon Papanastasiou

7

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19362675

Alberto Ferreira

8

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19362675

Florian Hartl

9

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19362675

Taiwo Fashola

10

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19362675

Peter Mesenbrink

11

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19362675

Philip N Sambrook

12

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19362675

HORIZON investigators

13

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19362675

language of work or name

0 references

publication date

1 April 2009

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19362675

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19362675

373

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19362675

9671

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19362675

1253-1263

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19362675

Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960250-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Use of oral corticosteroids and risk of fractures.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960250-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Oral corticosteroids and fracture risk: relationship to daily and cumulative doses

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960250-6

7 January 2021

based on heuristic

inferred from DOI database lookup

The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960250-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960250-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Evidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: a consensus document of the Belgian Bone Club

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960250-6

7 January 2021

based on heuristic

inferred from DOI database lookup

The pathogenesis, epidemiology and management of glucocorticoid-induced osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960250-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960250-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960250-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960250-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Tolerability and compliance with risedronate in clinical practice

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960250-6

7 January 2021

based on heuristic

inferred from DOI database lookup

The effect of dosing frequency on compliance and persistence with bisphosphonate therapy in postmenopausal women: a comparison of studies in the United States, the United Kingdom, and France

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960250-6

7 January 2021

based on heuristic

inferred from DOI database lookup

A systematic review of persistence and compliance with bisphosphonates for osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960250-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Non-compliance: the Achilles' heel of anti-fracture efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960250-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960250-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Consequences of poor compliance with bisphosphonates

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960250-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Transmission of human herpesvirus 8 by blood transfusion

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960250-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Zoledronic acid and clinical fractures and mortality after hip fracture

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960250-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Prediction of creatinine clearance from serum creatinine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960250-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Editorial: The determination of circulating 25-hydroxyvitamin D: no easy task

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960250-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Vertebral fracture assessment using a semiquantitative technique.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960250-6

7 January 2021

based on heuristic

inferred from DOI database lookup

EuroQol--a new facility for the measurement of health-related quality of life

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960250-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Glucocorticoid-induced osteoporosis: pathophysiology and therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960250-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960250-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960250-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Prevalence and incidence of vertebral deformities

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960250-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Glucocorticoid-induced osteoporosis: a systematic review and cost-utility analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960250-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Prevention and treatment of glucocorticoid-induced osteoporosis: a comparison of calcitriol, vitamin D plus calcium, and alendronate plus calcium.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960250-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960250-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Teriparatide or alendronate in glucocorticoid-induced osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960250-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety considerations with bisphosphonates for the treatment of osteoporosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960250-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(09)60250-6

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19362675

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19362675

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46052972&oldid=2089594248"